PBYI
Puma Biotechnology Inc
Halal Rating :
Last Price
$2.97
Last updated:
Market Cap
-
7D Change
-3.57%
1 Year Change
-40.36%
Company Overview
Industries
Exchange
Next Earnings Date
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products to enhance cancer care. Their primary product is NERLYNX® (neratinib), an oral medication used for the extended adjuvant treatment of HER2-positive early stage breast cancer and metastatic HER2-positive breast cancer.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $80.54m | $61.56m | - | $3.1m | 0.00% | 5.04% |
| June 30, 2024 | $47.08m | $52.63m | - | $3.37m | 0.00% | 6.41% |
| March 31, 2024 | $43.77m | $49.42m | - | $3.36m | 0.00% | 6.80% |
Company Impact
Help us evaluate Puma Biotechnology Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.